Related Experiment Videos
Systemic therapy for gynecologic cancer
1University of Texas MD Anderson Cancer Center, Houston.
Abstract:
Several provocative studies in gynecologic cancer were recently presented. Long-term follow-up of ovarian cancer patients has confirmed the clinical impression of a low survival. Novel classes of active chemotherapeutics are the second-generation topoisomerase I inhibitors, irinotecan (CPT-11) and topotecan, and the taxanes, Taxol (Bristol-Meyers, Wallingford, CT) and Taxotere (Rhone-Poulenc Rorer, Antony, France). Dose intensity remains an intriguing issue. Biologic agents, including monoclonal antibodies, are being developed for palliation of ascites. In cervical cancer, use of retinoids and interferons has opened up a new avenue of investigation. Use of the World Health Organization sophisticated scoring criteria has improved the primary treatment of trophoblastic disease. Advances in salvage therapy have been noted. Progress in the treatment of advanced endometrial cancer and uterine sarcomas is beginning.
Insights
Recent gynecologic cancer studies highlight novel chemotherapeutics like irinotecan and taxanes for ovarian cancer, alongside biologic agents for ascites palliation. Advances are also noted in cervical, trophoblastic, endometrial, and uterine sarcoma treatments.
Area of Science:
- Gynecologic Oncology
- Medical Oncology
- Chemotherapy
Background:
- Long-term ovarian cancer follow-up confirms poor survival rates.
- Novel chemotherapeutic agents are emerging for gynecologic malignancies.
- Biologic agents and new treatment strategies are under investigation.
Purpose of the Study:
- To review recent advancements in the treatment of various gynecologic cancers.
- To highlight novel therapeutic agents and approaches in gynecologic oncology.
- To discuss progress in managing ovarian, cervical, trophoblastic, endometrial, and uterine sarcoma diseases.
Main Methods:
- Review of recent studies presented in gynecologic oncology.
- Discussion of novel chemotherapeutics including topoisomerase I inhibitors and taxanes.
- Exploration of biologic agents, retinoids, interferons, and scoring criteria.
Main Results:
- Second-generation topoisomerase I inhibitors (irinotecan, topotecan) and taxanes show activity.
- Monoclonal antibodies are being developed for ascites palliation in ovarian cancer.
- Retinoids and interferons offer new avenues for cervical cancer treatment.
- Improved primary treatment for trophoblastic disease using WHO criteria.
- Advances noted in salvage therapy and treatment for advanced endometrial cancer and uterine sarcomas.
Conclusions:
- Significant progress is being made in the treatment of various gynecologic cancers.
- Novel therapeutic agents and strategies are expanding treatment options.
- Ongoing research promises improved outcomes for patients with gynecologic malignancies.